

15 June 2016 Australian Securities Exchange Announcement

Placement Update

Attached to this update is the Appendix 3B for the placement recently completed by Leaf Resources Ltd. The Company was offered an additional \$152,000 on the same terms as those announced on Monday 6th June 2016 and has accepted the extra amount.

Final details of the placement are that Leaf Resources has issued 8,770,000 ordinary shares at an issue price of \$0.10 as well as a conversion of 700,000 options exercisable at \$0.10 thereby raising a total of \$947,000.

In addition to the funds from the placement, the company is expecting to receive a total of over \$650,000 from Joint Venture research fees, the Export Market Development Grant program and the R & D Tax Rebate in the near future.

Funds raised from the placement and the collections detailed above will be used to continue the commercialisation of Leaf Resources' GlycellTM Process in the USA, Europe, Asia and Australia.

About Leaf Resources Ltd (ASX: LER)

Leaf Resources is commercialising the GlycellTM process.

The GlycellTM Process is an innovative technology that uses a low cost, recyclable, biodegradable reagent glycerol, in a simple process that breaks down plant biomass into lignin, cellulose and hemicellulose at low temperature and pressure. The cellulose is then converted to cellulosic sugars through enzymatic hydrolysis and the lignin, hemicellulose and glycerol become valuable co-products.

Cellulosic sugars are a major feedstock for green, renewable biobased chemicals, bioplastics and biofuels, products whose markets are multi \$billions and fast growing. Many biobased products can now economically replace petroleum based products.

The Glycell™ process can produce cellulosic sugars at under \$50 per tonne when co-products are included. This compares with \$220 per tonne for sugars produced from the conversion of corn starch, the cheapest alternative and \$280 per tonne for raw sugar.

By dramatically reducing the cost of the main feedstock for bio based chemicals, plastics and biofuels, the GlycellTM process has the potential to change the face of global renewable production.

Contacts:

Ken Richards (Managing Director) M: +61 403 385 051 Jay Hetzel (Chairman) M: +61 413 045 478

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/oo, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$

Leaf	Resources Limited	
ABN		
18 07	4 969 056	
We (t	he entity) give ASX the following	g information.
	1 - All issues	
You m	ust complete the relevant sections (attac	n sneets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully paid ordinary shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	9,470,000
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the	Fully paid ordinary shares
	conversion price and dates for conversion)	

Name of entity

⁺ See chapter 19 for defined terms.

Do the *securities rank equally 4 in all respects from the +issue Yes date with an existing +class of quoted +securities? If the additional +securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration shares a) 8,770,000 issued 5 to sophisticated investors at \$0.10 per share. b) 700,000 shares issued following the exercise of 700,000 options (expire 20/12/16) at exercise price of \$0.10 each Purpose of the issue 6 (If issued as consideration for To provide additional working the acquisition of assets, clearly capital for the commercialisation identify those assets) of the Company's GlycellTM process. Is the entity an +eligible entity 6a that has obtained security Yes holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder

passed

resolution under rule 7.1A was

Appendix 3B Page 2 04/03/2013

25 November 2015

⁺ See chapter 19 for defined terms.

6c	Number of *securities issued without security holder approval under rule 7.1	8,770,000
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	
6f	Number of *securities issued under an exception in rule 7.2	700,000
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	15 June 2016

⁺ See chapter 19 for defined terms.

8 Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
142,749,760	Fully paid ordinary shares

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
1,300,000 Exercisable at \$0.10, Expire 20/12/16	Options
2,625,000 Exercisable at \$0.10, Expire 17/12/17	Options
375,000 Exercisable at \$0.10 Expire 2/9/18	Options
1,000,000 Exercisable at \$0.10 Expire 28/10/18	Options

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
Date rights trading will begin (if applicable)	
Date rights trading will end (if applicable)	
How do security holders sell their entitlements <i>in full</i> through a broker?	
How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
How do security holders dispose of their entitlements (except by sale through a broker)?	
⁺ Issue date	
	plying for quotation of securities
	and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders Date rights trading will begin (if applicable) Date rights trading will end (if applicable) How do security holders sell their entitlements in full through a broker? How do security holders sell part of their entitlements through a broker and accept for the balance? How do security holders dispose of their entitlements (except by sale through a broker)? *Issue date 3 - Quotation of securities at the enemployee incentive share securities at the enemployee incentive share securities when the securities when the securities and the enemployee incentive share securities when the securities when the securities and the enemployee incentive share securities when the securities and the enemployee incentive share securities when the securities are the enemployee incentive share securities when the securities are the enemployee incentive share securities when the securities are the enemployee incentive share securities when the securities are the enemployee incentive share securities when the securities are the enemployee incentive share securities when the securities are the enemployee incentive share securities when the securities are the enemployee incentive share securities when the securities are the enemployee incentive share securities when the securities are the securities are the enemployee incentive share securities when the securities are the securities are the enemployee incentive share securities when the securities are the enemployee incentive share securities when the securities are the securities when the securities are the s

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to docume	e you are providing the information or
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additiona *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 100,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

⁺ See chapter 19 for defined terms.

Entitie	Entities that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Number	+Class

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

	AH TOM IN I AL.	15/06/2016
Sign here:	1474 er arayya	Date:
J. J		2 400.

Company sécretary

Print name: Helen Pennisi

⁺ See chapter 19 for defined terms.

Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	113,357,067	
Add the following:		
 Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 	10,192,373	
 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval 	874,132	
 Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period 		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period		
"A"	124,423,572	

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	18,663,536	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	28/10/15 3,736,883	
Under an exception in rule 7.2	19/11/15 4,635,971	
Under rule 7.1A	01/12/15 1,183,334	
With security holder approval under rule 7.1 or rule 7.4	13/06/16 8,770,000	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	18,326,188	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15		
Note: number must be same as shown in Step 2	18,663,536	
Subtract "C"		
Note: number must be same as shown in Step 3	18,326,188	
Total ["A" x 0.15] – "C"	337,348	
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	124,423,572
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	12,442,357
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	
"E"	Nil

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	12,442,357
Subtract "E"	
Note: number must be same as shown in Step 3	Nil
Total ["A" x 0.10] – "E"	
	12,442,357
	Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.